Revenue
No reported data
Drugs Made In America Acquisition Corp. (DMAA)
Price—Loading quote
Net income
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | |
|---|---|
| Operating expenses | $141,976 |
| Operating income | −$2.8M |
| Net income | $5.9M |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 18, 2025Form 4 | Drugs Made In America Acquisition LLCTenPercentOwner | BuyOrdinary shares | 30.0K | — | — | 4.19M |
| Feb 18, 2025Form 4 | Drugs Made In America Acquisition LLCTenPercentOwner | BuyRights to receive ordinary shares · derivative | 30.0K | — | — | 430.0K |
| Feb 18, 2025Form 4 | Stockwell LynnCEO and Exe. Chair of Board | BuyOrdinary shares · indirect | 30.0K | — | — | 4.19M |
| Feb 18, 2025Form 4 | Stockwell LynnCEO and Exe. Chair of Board | BuyRights to receive ordinary shares · derivative · indirect | 30.0K | — | — | 430.0K |
| Jan 29, 2025Form 4 | Drugs Made In America Acquisition LLCTenPercentOwner | SellOrdinary shares | 5.70M | — | — | 4.16M |